[Acarbose (glucobai) effects on lipid metabolism in patients with non-insulin dependent diabetes mellitus].
OBJECTIVE
To investigate the effect of acarbose, intestinal alpha-glucosidase inhibitor, on lipid metabolism in patients with non-insulin-dependent diabetes mellitus (NIDDM).


METHODS
Glucobai was given for 6 months in a dose 300 mg/day to 63 NIDDM patients aged 40-69 years. The examination covered indices of glycemia, glycosylated hemoglobin, pancreatic insulin secretion, total cholesterol (TC), triglycerides (TG), HDLP and LDLP cholesterol, atherogenic index.


RESULTS
Glucobai has improved glycemic profile, reduced insulinemia and body mass index, TC, TG, atherogenic index. Blood levels of HDLP cholesterol elevated by 62%.


CONCLUSIONS
Long-term intake of acarbose improves carbohydrate metabolism and produces a hypolipidemic effect.
Rosliakova
L V
LV
Roĭtman
A P
AP
Ametov
A S
AS
Dolgov
V V
VV
D020909:Acarbose / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood*
D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D014280:Triglycerides; D020909:Acarbose